Bentazepam

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of bentazepam
General
Non-proprietary name Bentazepam
other names

5-phenyl-1,3,6,7,8,9-hexahydro-2 H - [1] benzothieno [2,3- e ] [1,4] diazepin-2-one

Molecular formula C 17 H 16 N 2 OS
External identifiers / databases
CAS number 29462-18-8
EC number 608-362-7
ECHA InfoCard 100.123.659
PubChem 34592
ChemSpider 11248641
Wikidata Q1421936
Drug information
ATC code

N05 BA24

Drug class
properties
Molar mass 296.38 g · mol -1
Physical state

firmly

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
07 - Warning 09 - Dangerous for the environment

Caution

H and P phrases H: 317-413
P: ?
Toxicological data
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Bentazepam is a benzodiazepine analog from the group of thienodiazepines , which is mainly used as an anxiolytic for anxiety disorders and panic attacks . In the treatment of anxiety, it is said to have effects comparable to those of clorazepate or ketazolam , with the elimination half-life being relatively short at an average of 3 hours.

Bentazepam was approved in Spain in 1980 and marketed there under the trade name Tiadipona . Areas of application were anxiety states with or without the accompanying functional or organic disorders. It is still available in Uruguay.

The short elimination half-life and the low potency (50 mg bentazepam correspond to approx. 10 mg diazepam) make it appear to be disadvantageous for the treatment of a chronic disease. An overdose of bentazepam can in severe cases lead to coma and respiratory failure. Severe liver damage and hepatitis have been linked with the use of bentazepam. Liver failure can occur in rare cases, which is why all patients taking bentazepam should have their liver functions monitored regularly.

Like all anxiolytics from the benzodiazepine class, bentazepam has a high potential for dependence and abuse .

Individual evidence

  1. ↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of 5-phenyl-3,4,6,7,8,9-hexahydro- [1] benzothiolo [2,3-e] [1,4] diazepin-2-ones is shown, which is derived from a self-classification by distributors in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on June 18, 2019.
  2. ↑ a b MP Fernándex-Tomé, JA Fuentes, R Madroñero, J del Río: Pharmacological properties of 6,7-tetramethylene-5-phenyl-1,2-dihydro-3H-thieno [2,3-e] (1, 4) -diazepin-2-one (QM-6008, thiadipone), a new psychotropic drug. . In: drug research . 25, No. 6, 1975, pp. 926-934. PMID 1174332 .
  3. ↑ DE Patent 2005276
  4. ↑ Pedreira V., Blanco J., Rodrigue MV, Hierro JF, de Juana IO, Gallego MJA, Velasco J .: A comparison of bentazepam versus ketazolam in anxiety disorders diagnosed according to DSM -III-R. . In: Current Therapeutic Research . 55, No. 3, March 1994, pp. 348-355. doi : 10.1016 / S0011-393X (05) 80178-X .
  5. ↑ Higueras A., Sanmatias JJ, Padial E., Garrido J., Otero FJ, Velasco J .: Bentazepam versus cloracepate in the treatment of anxiety disorders. . In: Current Therapeutic Research . 52, No. 1, July 1992, pp. 46-52. doi : 10.1016 / S0011-393X (05) 80435-7 .
  6. ^ F Gonzalez López, EL Mariño, A Dominguez-Gil: Pharmacokinetics of tiadipone: a new anxiolytic . In: International journal of clinical pharmacology, therapy, and toxicology . 24, No. 9, 1986, pp. 482-4. PMID 2877954 .
  7. ↑ CI Colino, CF Lastra, FG López, A Ledesma, EL Mariño: Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients. . In: International journal of clinical pharmacology, therapy, and toxicology . 29, No. 11, 1991, pp. 457-62. PMID 1800395 .
  8. ↑ Information on all trademarks registered through the Madrid System .: Tiadipona® in the Madrid System. Real-time status - WIPO reference 50513901. In: WIPO Madrid Monitor. WIPO, September 4, 1986, accessed February 22, 2019 .
  9. ↑ Erika Montes Gómez, Mercedes Plasencia Núñez. Ana Teresa López Navarro, Mª Elidia Guerra Rodríguez, José Luis Castellano Cabrera, Ángela Martín Morales, Fidelina de la Nuez Viera: DESPRESCRIPCIÓN DE BENZODIAZEPINAS E HIPNÓTICOS Z . In: SERVICIO CANARIO DE LA SALUD (ed.): Bolcan . tape 2 , no. 9 . Servicio Canario de la Salud, September 2017, p. 3 (Spanish, gobiernodecanarias.org [PDF; accessed February 2, 2019]).
  10. ↑ FA Rivas López, F López Soriano, A Mendoza Cerezo, J Jiménez Ferré, JI Azurmendi Rodríguez, De La Rubia Nieto: Mixed benzodiazepine poisoning and reversal with flumazenil (Ro 15-1788) . In: Revista espanola de anestesiologia y reanimacion . 36, No. 1, 1989, pp. 48-50. PMID 2565591 .
  11. ↑ Albert Tuca: utilidad Clinica del acetato de megestrol para la ganancia de peso en los con enfermos neoplasia y caquexia . In: Medicina Clinica . 120, No. 17, 2003, p. 678. doi : 10.1157 / 13047309 .
  12. ^ Andrade RJ, Lucena MI, Alcantara R, Fraile JM: Bentazepam-associated chronic liver disease. . In: Lancet . 343, No. 8901, 1994, p. 860. doi : 10.1016 / S0140-6736 (94) 92065-6 . PMID 7908109 .
  13. ↑ RJ Andrade, MI Lucena, J Aguilar, MD Lazo, R Camargo, P Moreno, MD García-Escaño, A Marquez, R Alcántara, G. Alcáin: Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity . In: Digestive Diseases and Sciences . 45, No. 7, 2000, pp. 1400-4. doi : 10.1023 / A: 1005520523502 . PMID 10961721 .